February 11, 2021

Tocilizumab for COVID-19 – results from the RECOVERY trial

We invited journalists to join Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY trial, who provided results on the use of anti-inflammatory treatment, tocilizumab, as a treatment for patients hospitalised with COVID-19.

Speakers included:

Prof Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, and Chief Investigator of the RECOVERY trial

Prof Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Deputy Chief Investigator of the RECOVERY trial

This Briefing was accompanied by an SMC Roundup of Comments.